MedImmune CEO Talks Finance and Science
143623
David Mott, a Dartmouth-educated Wall Street investment banker, is increasingly leveraging his reputation in the local and national biotech communities.-The Washington Post
371145
As drug makers are increasingly scrutinized for their relationships to researchers, the Cleveland Clinic Foundation's chief academic officer is finding himself under the spotlight.
549694
When it comes to Microsoft, IT pros still want to hear more about security, Linux and product futures. CEO Steve Ballmer did his best to accommodate them Wednesday morning in a keynote speech at the Gartner Symposium ITXpo in Orlando, Fla.
615665
Over three decades, Bob Klein amassed a fortune by building and financing low-income housing. After his 14-year-old son was diagnosed with diabetes in 2001, however, he redirected his considerable political clout and business savvy. The longtime Democrat has since become one of the biggest private patrons of human embryonic stem cell research &#151; medical technology that many scientists believe can someday cure a wide range of ailments, including diabetes.
366184
The California Institute for Regenerative Medicine's new president sits down for an exclusive interview with Wired News as the agency prepares to distribute $263 million for new stem cell facilities.
433289
The large-cap drugmaker keeps giving investors reason to cheer.
219262
SAN FRANCISCO  - IBM, Intel, Microsoft and other tech companies are increasingly betting that the health care industry will help them grow as their traditional markets mature. Microsoft CEO Steve Ballmer is to kick off a health care tech conference in New Orleans today. The health care Information and Management Systems Society show is expected to draw 900 exhibitors and 25,000 doctors, hospital staffers and others.
768235
Bankrate's new CEO shares the art of tracking personal finance data.
34815
The Principal Financial GroupÂs chief executive spoke about the recent pension reform law, defined benefits and wellness.
764344
The anti-industry crusader targets pharmaceuticals.
587650
The Motley Fool - In May, I had the opportunity to hear Michael Mauboussin, chief investment strategist at Legg Mason (NYSE: LM - News), speak at the NanoBusiness Alliance's annual conference in New York. It was my good fortune that his new book had just come out, More Than You Know: Finding Financial Wisdom in Unconventional Places, and he was signing copies afterward.
112584
Medarex (Nasdaq: MEDX) is best known for being a leader in antibody technology with its capabilities for generating human antibodies in mice.
679054
The flu shot shortage offers some food for thought for investors.
440113
Pharmacopeia presents at an investors' conference.
709018
A new strategy aiming to attract global investment in the field of life sciences is launched.
634339
The move comes just months after Jon Symonds completed the $15.2 billion purchase of MedImmune, which some investors considered too expensive.
334120
Sir Magdi Yacoub on transplant medicine, Nobel Prize winners and Mozart.